Navigation Links
China Sky One Medical Prepares to Launch 13 New Products
Date:3/22/2010

HARBIN, China, March 22 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

    Since earlier SFDA approvals of these products, the Company has been
testing production quality and evaluating stability of the final manufacturing
process in preparation for commercial production. Commercialization
preparation for these 13 products is now complete or nearly complete and the
Company anticipates launching the products based on the following marketing
timetable.



    No.    Product Name          Description                   Expected
                                                               Marketing
                                                                 Time
    1      Oxymetazoline      To treat acute and chronic      March 2010
           Hydrochloride      rhinitis, sinusitis and
           Nasal Drops        allergic rhinitis

    2      Moschus Liniment   To relieve the pain from        March 2010
           for pain relief    scathe, wound, rheumatism and
                              arthrosis

    3      Ftibamzone         To treat herpes and fungal      April 2010
           Liniment           skin infection.

    4      Tobramycin Eye     To treat acute infection on     April 2010
           Drops              eyelids

    5      Calcium Folinate   An auxiliary therapy for sprue  May 2010
           Injection          (a disease of the small
                              intestine), malnutrition,
                              pregnancy- or infancy-related
                              megaloblastic anemia, and
                              colonic and rectal cancer

    6      Sodium             To treat allergic               May 2010
           Cromoglicate Eye   conjunctivitis
           Drops

    7      Aciclovir Gel      To treat the skin infection     June 2010
                              due to varicella-zoster virus
                              and the herpes simplex virus

    8      Antiasthma cream   To treat cough, asthma and      June 2010
                              chronic bronchitis

    9      Naphazoline        For the sterilization and       June 2010
           Hydrochloride      rheum prevention and for the
           Chlorpheniramine   treatment of rheumatic
           Maleate and        diseases
           Benzalkonium
           Bromide Spray

    10     Skincare Cream     To treat skin diseases such as  July 2010
                              acne, bottle nose,
                              chromophytosis and vitiligo

    11     Nasal Drop         To treat the sniffles           August 2010

    12     Propylgallate for  To treat cerebro-vascular       August 2010
           Injection          infarction, angina,
                              hypertention and coronary
                              heart diseases

    13     Dithranol          To treat different types of     September 2010
           ointment           psoriasis, such as plaque
                              psoriasis, guttate psoriasis
                              and hypertrophy psoriasis

"We look forward to the near-term launch of several products from our R&D pipeline and are now working on the sales forecast for these products diligently. Looking ahead, we are committed to provide more transparency to the investment community about the progress of our rich R&D pipeline. We expect to continue to diversify our rich product portfolio to strengthen the Company's competitive position and support sustainable long-term growth," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the production timeline and its effect on the Company's operational results. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the ability to launch new products, market acceptance of new product launches, the effect of changing economic conditions in The People's Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451- 87032617
     Email: stanleyhao@cski.com.cn

    Investor Relations Contact:
     CCG Investor Relations
     Ms. Lei Huang, Account Manager
     Tel:   +1-646-833-3417
     Email: lei.huang@ccgir.com
     Web:   http://www.ccgirasia.com

     Ms. Mabel Zhang, Vice President
     Tel:   +1-310-954-1353
     Email: mabel.zhang@ccgir.com

SOURCE China Sky One Medical, Inc.

Back to top

RELATED LINKS
http://www.cski.com.cn

'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Biologic Products Schedules Conference Call to Discuss Fourth Quarter and Full Year 2009 Results
2. China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology
3. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
4. China Pharma Holdings, Inc. Reports Full Year 2009 Financial Results
5. China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference
6. China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results
7. China Nepstar Chain Drugstore Announces Annual Dividend
8. Chinas leading electronic systems design event to highlight next-generation medical, automotive and green power technologies
9. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
10. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
11. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):